Sertraline

Drug Profile

Sertraline

Alternative Names: Aremis; Besitran; CP 51974; CP 51974 01; Gladem; J Zoloft; Lustral; Serad; Serlain; Tatig; Zoloft

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Pfizer
  • Class Amines; Antidepressants; Anxiolytics; Naphthalenes; Small molecules
  • Mechanism of Action Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Major depressive disorder; Obsessive-compulsive disorders; Panic disorder; Post-traumatic stress disorders; Premenstrual dysphoric disorder; Social phobia
  • No development reported Generalised anxiety disorder
  • Discontinued Obesity; Premature ejaculation

Most Recent Events

  • 01 Sep 2016 Pfizer completes a phase I trial in Healthy volunteers in Belgium (NCT02651623)
  • 15 Mar 2016 Biomarkers information updated
  • 01 Jan 2016 Pfizer initiates enrolment in a phase I trial in Healthy volunteers in Belgium (NCT02651623)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top